
ãããäºé²ãµããªãããŸããããšèãããŠãèªåãå°ã£ã話
ãå çãããäºé²ã«ãããµããªã£ãŠãããŸããã
倿¥ã§ãšãã©ãèãããã
ããèããŠãã人ã¯ãå¥åº·æèãé«ãã人éããã¯ãåããŠããããžã ã«ãè¡ã£ãŠããããããã€ã³ã飲ãã§ããããç¡ç ã¢ããªã®ã¹ã³ã¢ãŸã§ç¢ºèªããŠããã
ãã ã話ãç¶ãããšå°ãåŒã£ãããã
ãããªèã調ã¹ãèšæ¶ããªããèçãŠã€ã«ã¹ã®æ€æ»æŽãææ§ã ãäŒé£ã¯é±ã«äœåããã£ãŠãå¯ãåãŸã§é ãæ®ã£ãŠãããæåžã£ãŠããã¿ãã³ã®è©±ã¯ããªããå¥åº·çžè«ã®æåŸã«åºãŠããã
ãããããšããèªåã¯ãã€ãåãããšãèããã
ããäºé²ã¯ãäœãè¶³ãããããäœãæ®ãããŸãŸã«ããŠãããã®ã»ãã倧äºãªããšãããã
èªåãæ°ããè«æãæ°ããæ€æ»ã¯å¥œãã ããæ°ãããµããªãããè²·ããããªããè²·ã£ãŠãåŠ»ã«æãããŠãæšãŠããããŸã§ãæ§åŒçŸã ã
ãã ãé çªãééãããšè¿·åã«ãªãã
ã¿ãã³ãæ®ãããŸãŸãæé žåãµããªã飲ã
æ¯æ©é£²ã¿ãªãããèèã«ãããµããªãæ¢ã
ææã«é¢ããæ€æ»æŽãææ§ãªãŸãŸãé«é¡ãªå šèº«æ€æ»ãåãã
穎ã®ç©ºãããã±ãã«ãæ°Žãæ³šãã§ããæãã«è¿ããæ°Žãè¶³ãåã«ã穎ãå¡ãã
ããã¯ãéºäŒã幎霢ãå¶ç¶ãææãç°å¢ãçæŽ»ãå»çã¢ã¯ã»ã¹ã絡ãã§èµ·ãããã ãããããã«ãªã£ãäžäººã®äººçãããšããæ¯ãè¿ã£ãŠãåå ãäžã€ã«æ±ºããããšã¯ã§ããªããããã§ããããããã®èªåã«ã€ããŠãæžããããããªã¹ã¯ã®é çªã¯ããã

äžçã®ããã®37.8%ã¯ãæžããããªã¹ã¯ãšé¢ä¿ããŠãã
2026幎ãNature Medicineã«å€§ããªè§£æãçºè¡šãããã185ã«åœã36çš®é¡ã®ããã察象ã«ã30ã®ãä¿®æ£å¯èœãªã¹ã¯å åããããã®ã©ããããã«é¢ä¿ããŠããããæšå®ããç ç©¶ã ¹âŸâµâŸã
ä¿®æ£å¯èœãªã¹ã¯å åãšããã®ã¯ãçæŽ»ãç°å¢ãã ãã§æžãããèŠå ã®ããšã§ãã¿ãã³ãé ãææãéåäžè¶³ã倪ãããã空æ°ã®æ±ãã玫å€ç·ãè·å Žã§ã®æé²ãªã©ãå ¥ãã幎霢ãéºäŒã®ããã«ãèªåã®åŽã§å€ããããªããã®ã¯å«ãŸãªãã
2022幎ã®äžçã®æ°èŠããçŽ1870äžä»¶ã®ãã¡ãçŽ710äžä»¶ã37.8%ããã®30ã®å åã«èµ·å ãããšæšå®ããããå¯äžã倧ããã£ãé ã«ãå«ç 15.1%ãææ10.2%ã飲é 3.2%ãèºãããèãããåå®®é žããã®3ã€ã§ãæžãããããã®çŽååãå ããŠãããIARC/WHOã¯ãã®çµæããäžçã®ããã®æå€§4å²ã¯äºé²ã§ããããšçºè¡šããŠãã²âŸÂ³âŸâŽâŸã

ãã ã37.8%ã¯äžçå šäœã®æšå®ã§ãããªãäžäººãé 匵ãã°ããã®ãªã¹ã¯ã37.8%æžãããšããæ°åãšã¯éããæžãããäœå°ã®äžã«ã¯ãã¿ãã³ãåžããããç°å¢ãé ãæãã«ããæåãã¯ã¯ãã³ãæ€æ»ãå±ãã«ããå°åãè·å Žã§ã®æé²ã空æ°ã®æ±ãã玫å€ç·å¯Ÿçã®äžè¶³ãŸã§ã瀟äŒã®ä»çµã¿ãå ¥ã£ãŠããã
ãã®æ°åã®äœ¿ãã©ããã¯ãäœããæžãããã®é çªã決ããããšã ã
ããäºé²ãµããªã®åã«ããŸã ã¿ãã³ãæ®ã£ãŠããªãã
ä»åã®è§£æã§ãå«ç ã¯å šæ°èŠããã®15.1%ã«é¢ä¿ããŠãããç·æ§ã§ã¯23%ã§ãã»ãã®èŠå ãšæ¯ã¹ãŠå¥æ Œã«å€§ããã
ä»ãåžã£ãŠãããªããããäºé²ãµããªãæ¢ãåã«ãŸãã¿ãã³ã ã
ããããæ¹ãããã®ã¯åãã£ãŠãããã§ãã
åŒåžåšå ç§ã®å€æ¥ã§ãäœåãèãããåãã£ãŠããŠãããããããªãã
ãã³ãã³äŸåãæå¿ã®åŒ±ãã§çã¥ãããšããããŠã倱æãããäŸåãšããŠæ±ã£ãŠãçŠç 倿¥ããã³ãã³ä»£æ¿çæ³ãå æè¬ãå®¶æãè·å Žã®ç°å¢èª¿æŽãšãã£ãææ®µã䜿ã£ãã»ããããã
ã¿ãã³ãæ®ãããŸãŸæé žåãµããªãè¶³ããšãäœãèµ·ãããã1990幎代ã«ãå«ç è ã«Î²ã«ããã³ã®ãµããªã飲ãŸãããèºãããæžããã調ã¹ãå€§èŠæš¡è©Šéšããã£ããç·é»è²éèãå€ãé£ã¹ã人ã§èºãããå°ãªãããšãã芳å¯ããŒã¿ããã£ãããã ãæåŸ ãããŠããããçµæã¯éã ã£ãã
ATBC詊éšã§ã¯ãβã«ããã³ã飲ãã ç·æ§å«ç è ã§èºãããå¢ããâ¶âŸãCARET詊éšã§ããå«ç æŽãã¢ã¹ãã¹ãæé²ã®ããé«ãªã¹ã¯ã®äººã§Î²ã«ããã³ãšãã¿ãã³Aã®çµã¿åãããèºãããå¢ããã詊éšã¯éäžã§æ¢ãŸã£ãâ·âŸãå¥åº·ãªç·æ§ã§ãããã¿ãã³Eã®ãµããªã§åç«è ºãããå¢ãã詊éšãããâžâŸã
ãæé žåã§å®ãããšããçãããé广ã«ãªã£ãã
ã©ãããç¹å®ã®æåããµããªã§é«çšéã«ãæ°å¹Žé飲ã¿ç¶ãã詊éšã ãéèãæ®æ®µã®é£äºããæãéã¯ããã®è©Šéšã®ç¯å²ã«å ¥ã£ãŠããªãã
ææã®ãªã¹ã¯ã¯ãæ€æ»ãšæ²»çãšã¯ã¯ãã³ã§æžãã
å«ç ã®æ¬¡ã«å€§ããã£ãã®ãææã§ãæ°èŠããã®10.2%ã«é¢ä¿ããŠããã身è¿ãªãšããã§ã¯ãèãããšãããªèãåå®®é žãããšHPVãèãããšBåã»Cåèçã ã
ããã¯ãé£äºãéåãå€ããã ãã§ã¯æžãããªããæ€æ»ã§èŠã€ããŠæ²»çã«ã€ãªããããã¯ã¯ãã³ã§é²ãããããªèãèŠã€ããã°é€èãå»åž«ãšçžè«ããèçãŠã€ã«ã¹ãèŠã€ããã°å°éå»ã§æ²»çãçžè«ããâ¹âŸãHPVãšBåèçã¯ã察象ã«å ¥ã£ãŠããã°ã¯ã¯ãã³ã§é²ããåå®®é žããæ€èšºãã幎霢ã«åãããŠåããã
å°å³ã ããåãåŽãšããŠã¯å€§ãããé«é¡ãªå šèº«æ€æ»ãè¶³ãåã«ããã®æ€æ»æŽãæ²»çæŽãã¯ã¯ãã³æŽã確èªãããé çªãšããŠã¯ããã¡ãã®ã»ãããã£ãšçãããã
ã©ããŸã§åãããããã¯ãå¹Žéœ¢ãæ¢åŸæŽãäœãã§ããå°åãèªæ²»äœã®å¶åºŠã§å€ãããããã§ããèªåã¯ã©ãã ã£ãããäžåºŠç¢ºèªãã䟡å€ã¯ããã
é ã¯èšé²ãã
飲é ã¯ãå šæ°èŠããã®3.2%ã«é¢ä¿ããŠãããå«ç ãææããã¯å°ããããäŒé£ãå€ã人ã«ã¯ç¡èŠãã«ããæ°åã ã
æã¯ãé©éã®é ã¯äœã«ããããšããè©±ãæ ¹åŒ·ãã£ããããããJã«ãŒãã ããã®èª¬ã¯ãè¿å¹Žã®ç ç©¶ã§æ ¹æ ã匱ããªã£ããéå»ã«äœãå£ããŠé ãããã人ãã飲ãŸãªã人ãã«æ··ãã£ãŠããåé¡ãªã©ãåãã£ãŠããŠããå°ã飲ãäººã®æ¹ãå¥åº·ããšã¯èšãã«ãããªã£ã¹â°âŸãå°ãªããšããããªã¹ã¯ãšãã軞ã§ã¯ãé ãå¥åº·æ³ãšããŠæ±ããªãã»ããããã
é ã«ã¯ãæ¥åŸ ãäŒé£ãä»äºã®ä»ãåããå®¶æãšã®æéã奜ããªåºã人çã®æ¥œãã¿ãã€ããŠãããå»åŠã ãã§ã¯å²ãåããªããèªåãå€ã§é ã¯é£²ããã ããããŒã宣èšã®å»è ã«ã¯ãªããªãã
ãã ããŒãã«ã§ãããªãããããäžçªãªã¹ã¯ã¯äœãããŒãã«ããªããªããèšé²ãããé±ã«äœæ¥ãäœãã©ãããã飲ãã§ããããå¯ãäœæéåãŸã§é£²ãã§ããããé¡ãèµ€ããªãäœè³ªããèæ©èœãèèªèãå°¿é žãè¡å§ãç¡ç ã®è³ªãã©ãå€ããããèšé²ããããšãã©ããæžãããæ±ºãããããé ããäœã«ãããæªãããã§èªãããããã°ãšããŠæ±ãã»ãããèªåã«ã¯åã£ãŠããã
éåãè¶³ããŠããå šéšã¯ãã£ã©ã«ãªããªã
éåéãå€ã人ã§ã¯ãäžéšã®ãããå°ãªãããšãå ±åãããŠãã¹¹âŸãæè¿ã¯ãŠã§ã¢ã©ãã«ã§æž¬ã£ãæ¥åžžã®çãé«åŒ·åºŠã®åããšãããã®çºçã調ã¹ãç ç©¶ããã¹²âŸã
ããã§ããéåã§ã¿ãã³ãé ãæ€æ»ã®æãããã£ã©ã«ã¯ã§ããªããèªåã¯éåããåã£ãããšã®åå°ã ãšèããŠãããçèãå¿èºæ©èœãè¡ç³ãç¡ç ãæ°åãšãéåãæ¯ãããã®ã¯å€ãããã ãå«ç ãææã飲é ãè·å Žã§ã®æé²ã®ãããªå€§ãããã®ãèŠãªããµãããå 眪笊ã«ã¯ãªããªãã
å¿ãã人ã»ã©ãå¥åº·æè³ã®åã«æåããæ±ºãã
çµå¶è ãå¿ããããžãã¹ããŒãœã³ã蚺ãŠãããšãå¥åº·ãæè³ã§è§£æ±ºããããšãã人ãå€ããããæ€æ»ãåããŠããããµããªã飲ã¿ããããžã ã«è¡ããããç¡ç ããã€ã¹ãè²·ããããèªäœã¯æªããªãã
ãã ãã²ãšæã®ãµããªä»£ã§ãææã«é¢ããæ€æ»ãå¿ èŠãªã¯ã¯ãã³æŽã®ç¢ºèªãæžãã§ããŸãããšããããæè³ã®è©±ãªããé çªãéã«ãªã£ãŠããã
æè³ã®åã«ãæåããå¿ èŠãªããšããããæ¯æ©ã®é ãå¯ãçŽåã®é£äºããããé¢ä¿ãªããããšã«ããŠããæã®å«ç æŽãåããŠããªãæ€æ»ãããããå¢ããŠããäœéã座ãã£ã±ãªãã®ä»äºããããæ®ãããŸãŸäžã«å¥åº·æ³ãç©ãã§ãã垳尻ã¯åãã«ããã
倿¥ã§ãã䜿ãã®ã¯ãããŸãäžåã ãåãããšããããæ¹ã ãå šéšã¯ç¡çã§ããããããªãçŠé ã§ããªããªãããã€ãã®æåŸã®äžæ¯ãããããäŒé£ãæžãããªããªããç· ãã ãããããæ€æ»ãé¢åãªãããŸãèçãŠã€ã«ã¹ãšãããªèã®å±¥æŽã ã確èªãããå°ããããã©ãå°ããåŒãç®ã¯ç¶ãã
å¹³åã§èããæãã«ã€ããŠã¯ã以åãããªãã®äœã«ããŒããã©ãªãªã¯çµããªããã«æžãããéå£ã®å¹³åã¯ãããªãäžäººã®æé軞ãå®ã£ãŠãããªããããäºé²ã§ãåãã ã
ããäºé²ã§äœããè¶³ããããªã£ãããå ã«ç¢ºèªãã5ã€
ã¿ãã³ã¯æ®ã£ãŠããªãããä»ãåžã£ãŠãããªãããµããªããçŠç ã®ã»ããæ°åãšããŠå€§ãããäŸåãšããŠæ±ã
ææã«é¢ãã確èªã¯æããŠããªããããããªèãèçãŠã€ã«ã¹ãHPVã¯ã¯ãã³ãBåèçã¯ã¯ãã³ãåå®®é žããæ€èšºã®ãã¡ãèªåã®å¹Žéœ¢ãšæ¢åŸæŽã§å¿ èŠãªãã®ãå»çæ©é¢ã§ç¢ºèªãããèŠã€ãã£ãããæ²»çãŸã§çžè«ãã
é ã¯éãšé »åºŠãèšé²ããŠããããæ¯æ¥ãé±ã«äœåããå¯ãçŽåãŸã§æ®ã£ãŠããªãããé¡ãèµ€ããªãäœè³ªããŸã§
äœéãå èèèªãéåäžè¶³ãåŸåãã«ããŠããªãããæ¯å¹Žã®å€åã¯å°å³ã ããé·ãæéã§ã¯å¹ããŠãã
è·å Žã玫å€ç·ã空æ°ã®æé²ãäžäººã§æ±ããŠããªãããç£æ¥å»ãå®å šè¡çã®çªå£ãèªæ²»äœã®å¶åºŠã䜿ã
ã©ãã ãæ°ãã€ããŠããŠããããã«ãªã人ã¯ãããããã§ããèªåã®è¡åã§æžããããªã¹ã¯ã¯ããã
æããããããèŠãªããµããããªãã
å®å¿ãè²·ãåã«ããŸãäžåã ãåãã

ãããŸã§èªãã§ãã ãã£ãŠãããããšãããããŸããã
圹ã«ç«ã£ãããã¹ããããããããšããããå±ã¿ã«ãªããŸãã
èªåã®äœã§ã詊ããå¥åº·ã®è©±ããããããªããŒãã§ãæ°æ¥ã«1æ¬ãããåºããŠããŸãããã²ãã©ããŒããŠããããšå¬ããã§ãã
ãã£ãšæ·±ãç¥ãããæ¹ãžïŒé¢é£èšäºïŒ
⌠åã£ãããšã«ãéåãè¶³ããªã
1æ¥æ°åã®ãéåã®ã€ãŸã¿é£ããã§ããã«ãªã人ãå°ãªãã£ãïœVILPAãšããäºé²ïŒç¡æïŒ
ãé±150å以äžã®éåããšèšããããšèŸããªã人åãã®èšäºã§ããé§
ã®éæ®µãæ©æ©ããéãè·ç©ãéã¶ãããªçãé«åŒ·åºŠã®åãããã人ã§ãããã®çºçãã©ããããå°ãªãã£ãããæžããŠããŸãã
âŒ æ€æ»ãè¶³ããªããã©ãããè¶³ãã
å¥èšºã®ãªãã·ã§ã³æ€æ»ãå
šéšçãã«ããªããŠãããå
ç§å»ãèããé çªïŒã¡ã³ããŒéå®ïŒ
人éããã¯ãäŒç€Ÿå¥èšºã§ãé«ãæ¹ãéžã¹ã°å®å¿ããšèããã¡ãªäººåãã®èšäºã§ããè
¹éšãšã³ãŒããããªèã調ã¹ãABCæ€èšºããã§ãªãã³ãé žåèãšã³ãŒãPSAãã©ã®é çªã§æ€èšããããŸã§æžããŠããŸãã
ã¡ã³ããŒã·ãããDr.ãããã©ããã®ãç¥ãã
ã¡ã³ããŒã·ãããDr.ãããã©ãããéå¶ããŠããŸããXã»ç¡ænoteã§ã¯åºããªããããäžæ®µèžã¿èŸŒãã è©±ãæžããŠããŸãã
çµå¶è ã®äž»æ²»å»ãšããŠã倿¥ã§å®éã«è©±ããŠããå 容
è«æãèªã¿ãªããèªåã®äœã§è©Šãããå¹ããã»å¹ããªãã£ãèšé²
æ€æ»æ°å€ã®èªã¿æ¹ããµããªã»è¬ã®éžã³æ¹
ã¡ã³ããŒéå®ã®æ²ç€ºæ¿Q&A
æé¡1000åã§å šèšäºèªã¿æŸé¡ã§ããåããªãã£ããããè§£çŽã§ããŸããæ°ã«ãªã£ãæ¹ã¯ãèŠããŠã¿ãŠãã ããã
åèæç®
1) Fink H, Langselius O, Vignat J, et al. Global and regional cancer burden attributable to modifiable risk factors to inform prevention. Nature Medicine. 2026;32:1306-1315. doi:10.1038/s41591-026-04219-7. PMID:41634393.
2) World Health Organization and International Agency for Research on Cancer. Four in ten cancer cases could be prevented globally. Joint News Release. 2026幎2æ3æ¥.
3) International Agency for Research on Cancer. Press Release No.375. Four in ten cancer cases could be prevented globally. 2026幎2æ4æ¥.
4) International Agency for Research on Cancer. Global and regional cancer burden attributable to modifiable risk factors to inform prevention. Questions and Answers. 2026幎2æ4æ¥.
5) Nature Medicine. Modifiable risk factors drive a large share of the global cancer burden. Research Briefing. 2026;32:1201-1202. doi:10.1038/s41591-026-04310-z.
6) The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029-1035. doi:10.1056/NEJM199404143301501. PMID:8127329.
7) Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334(18):1150-1155. doi:10.1056/NEJM199605023341802. PMID:8602180.
8) Klein EA, Thompson IM Jr, Tangen CM, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556. doi:10.1001/jama.2011.1437. PMID:21990298.
9) åœç«ããç ç©¶ã»ã³ã¿ãŒããæ å ±ãµãŒãã¹. ç§åŠçæ ¹æ ã«åºã¥ãããäºé². 2026幎7æ14æ¥æŽæ°. https://ganjoho.jp/public/pre_scr/cause_prevention/evidence_based.html
10) Zhao J, Stockwell T, Naimi T, et al. Association Between Daily Alcohol Intake and Risk of All-Cause Mortality: A Systematic Review and Meta-analyses. JAMA Netw Open. 2023;6(3):e236185. doi:10.1001/jamanetworkopen.2023.6185. PMID:37000449.
11) Moore SC, Lee IM, Weiderpass E, et al. Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million Adults. JAMA Intern Med. 2016;176(6):816-825. doi:10.1001/jamainternmed.2016.1548. PMID:27183032.
12) Stamatakis E, Ahmadi MN, Friedenreich CM, et al. Vigorous Intermittent Lifestyle Physical Activity and Cancer Incidence Among Nonexercising Adults: The UK Biobank Accelerometry Study. JAMA Oncol. 2023;9(9):1255-1259. doi:10.1001/jamaoncol.2023.1830. PMID:37498576.
å»çå 責
æ¬èšäºã¯äžè¬çãªå¥åº·ã»å»åŠæ å ±ã®æäŸãç®çãšãããã®ã§ãããç¹å®ã®å人ã«å¯Ÿãã蚺æãæ²»çãå»åŠçå©èšãè¡ããã®ã§ã¯ãããŸããã
ããã®æ€èšºãã¯ã¯ãã³ãææçæ€æ»ãçŠç æ²»çã飲é ãéåãäœé管çãè·æ¥æé²ãžã®å¯Ÿå¿ã¯ãå¹Žéœ¢ãæ¢åŸæŽãå®¶ææŽãçŸåšã®æ²»çå 容ã§å€æãå€ãããŸããå¥åº·äžã®æžå¿µãããå Žåã¯ãå¿ ãå»çæ©é¢ã§çžè«ããŠãã ããã